Stoma Appliance Scheme – new and amended listings

This measure implements recommendations from the Stoma Product Assessment Panel for changes to the Stoma Appliance Scheme (SAS) Schedule. A stoma is a surgically created abdominal opening to which part of the large or small intestine or colon is attached.

Page last updated: 09 May 2017

PDF version: Stoma Appliance Scheme – new and amended listings (PDF 103 KB)

This measure provides for five new product listings, amendments to 12 product listings and eight product deletions. The scheme helps thousands of Australians to manage their stoma, which is often a consequence of disease of the intestine, such as cancer.

Why is this important?

This program ensures that eligible people with stomas are able to better manage their condition by providing 100 per cent subsidised access to stoma-related products.

The proposed addition of five new products will provide scheme participants with alternative options to similar products already listed, generally giving eligible people more than three options to choose from.

The proposed deletion of eight products from the scheme is due to the manufacturer ceasing production. These deletions will not impact people with stomas as the deleted products will be replaced by new versions and there are similar products still available on the scheme. The proposed removal of the price premium of one product is to address a listing error.

The stoma products that will now be subsidised include pouches, an adhesive remover spray, and a catheter.

A proposed reduction in unit price and/or amendment to the maximum monthly quantities for 10 products from subgroup 9(k) will ensure that the cost-effectiveness of products is maintained on the SAS Schedule.

Who will benefit?

Patients will be provided with additional and improved product options through both listing new products and amending existing listings of products on the scheme. There will be no adverse health impacts from deleting products because alternative and upgraded options are available.

Patients will continue to access fully subsidised stoma products at appropriate prices to manage their condition.

How much will this cost?

This measure will save $9.5 million from 2017–18 to 2020–21.

In this section